Sanofi-Aventis and Bristol-Myers Squibb received approval from the FDA for the sNDA for antiplatelet agent Plavix in the reduction in patients with acute ST-segment elevation myocardial infarction (STEMI) in the rate of death from any cause and the rate of a combined endpoint of re-infarction, stroke or death. STEMI is a severe acute heart attack in which a coronary artery is generally blocked completely. These blockages are caused by clot formation in the arteries, a life-threatening complicati...